Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Hepion highlights upcoming Phase 2 rencofilstat trials at NASH Congress

Todd Hobbs, M.D. and CMO of Hepion Pharmaceuticals (NASDAQ:HEPA), gave a clinical presentation entitled, “Rencofilstat (CRV431): A liver-targeting drug candidate for NASH and HCC” at the Global NASH Congress...

May 27, 2022

Developments

Cowen sees continued demand for Profound’s TULSA-PRO after AUA2022

“We continue to gain confidence in the disruptive potential of Profound Medical’s (NASDAQ:PROF; TSX:PRN) transurethral directional thermal ultrasound ablation treatment for prostate cancer, TULSA-PRO,” writes Cowen...

May 20, 2022

Developments

MindMed reports Phase 1 topline data with MM-110 in opioid withdrawal

Mind Medicine (NASDAQ:MNMD; NEO:MMED) reported favorable safety and tolerability results from a Phase 1 placebo-controlled trial designed to assess safety, tolerability, pharmacokinetics and neurocognitive effects of MM...

May 19, 2022

Developments

Profound Medical insiders add to holdings

Profound Medical (NASDAQ:PROF; TSX:PRN) independent lead director, Brian Ellacott, and chairman and CEO, Arun Menawat, purchased additional shares of Profound on Nasdaq after the company’s 2022 first quarter blackout...

May 19, 2022

Developments

Profound Medical’s TULSA-PRO front and center at AUA2022

The American Urological Association’s 2022 annual meeting featured multiple clinical presentations and product demonstrations of Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO to effectively and safely ablate...

May 18, 2022

Developments

Ampio board committee conducting internal investigation

An independent special committee of the board of Ampio Pharmaceuticals (NYSE American:AMPE), with the assistance of independent legal counsel, is in the process of conducting an internal investigation that relates to...

May 17, 2022

Developments

Lanier Biotherapeutics to present LNR125 poster at American Thoracic Society

Lanier Biotherapeutics will present a poster demonstrating the ability of its LNR 125 to inhibit Type 2 inflammation in models of asthma caused by both allergy and respiratory viral infection at the American Thoracic...

May 13, 2022

Developments

NeoTX acquires InterX to boost drug discovery

Closely-held NeoTX of Israel has acquired InterX, a drug discovery company utilizing advanced proprietary tools of biomolecular computation for the discovery and design of novel therapeutic molecules based on Nobel...

May 12, 2022

Developments

Check-Cap initiates U.S. pivotal trial of C-Scan

Check-Cap (NASDAQ:CHEK) initiated its U.S. pivotal trial of C-Scan to detect polyps before they become colorectal cancer at the Mayo Clinic in Rochester, Minn. The company has obtained Institutional review board...

May 11, 2022

Developments

MindMed collaborators present positive Phase 2 data of LSD in anxiety

Prof. Matthias Liechti and Dr. Friederike Holze, Mind Medicine’s (NASDAQ:MNMD; NEO:MMED) collaborators at University Hospital Basel presented positive topline data from a Phase 2 placebo-controlled investigator...

May 11, 2022

Developments

Three finalists announced for Bloom Burton Award

The finalists for the 2022 Bloom Burton Award are Frank Baylis, executive chairman, and Kris Shah, president of Baylis Medical Technologies; Pieter Cullis, co-founder and chairman, of Acuitas Therapeutics; and Jan...

May 10, 2022

Developments

Profound Medical nearly doubles Q1 revenue

Profound Medical (NASDAQ:PROF; TSX:PRN) posted revenue of $1.4-million in the first quarter, up 92%, from $711,000 in the year earlier quarter. In the latest period, the company generated $1.02-million from recurring...

May 9, 2022

Developments

iBio demonstrates efficacy of an IL-2 sparing anti-CD25 antibody in cancer

iBio (NYSE American:IBIO) is presenting a poster on IBIO-101, its monoclonal antibody candidate for the treatment of solid tumors, at Frontiers in Cancer Immunotherapy 2022 in New York May 9-11. Preclinical evaluation...

May 9, 2022

Developments

Athira Pharma extends open label extension AD studies with fosgonimeton

Athira Pharma (NASDAQ:ATHA) is extending the length of the current open label extension study for its Phase 3 LIFT-AD and Phase 2 ACT-AD studies of fosgonimeton for the treatment of mild-to-moderate Alzheimer’s...

May 9, 2022

Developments

Rani’s RaniPill wins Fast Company’s 2022 World Changing Ideas Award

Rani Therapeutics (NASDAQ:RANI) took top honors for its RaniPill capsule in the health category of Fast Company‘s 2022 World Changing Ideas. The RaniPill capsule is about the size of a standard fish oil pill...

May 3, 2022

Developments

Hepion Pharma, HepQuant in clinical collaboration for Phase 2b NASH trial

Hepion Pharmaceuticals (NASDAQ:HEPA) entered into a clinical collaboration with HepQuant, a closely-held Denver company with novel, proprietary investigational technology for evaluating liver function and health in...

May 3, 2022

Developments

iBio to present poster highlighting better glycosylation for antibodies produced in plants via its FastPharming System

iBio (NYSE American:IBIO) senior product manager, Rachel Jordan, Ph.D., will present a poster at the annual Protein & Antibody Engineering Summit conference in Boston this week titled, “Plant-Made Antibodies...

May 2, 2022

Developments

Profound Medical gets high marks from Cowen on KOL webinar for TULSA-PRO

A key opinion leader highlighted the numerous technology advancements and clinical advantages of Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO treatment of prostate diseases at a company hosted clinical education...

May 2, 2022

Developments

Limaca Medical receives FDA breakthrough device designation

The FDA granted closely-held Limaca Medical of Israel breakthrough device designation for its Precision-GI endoscopic ultrasound biopsy product. The Precision-GI device is designed to obtain tumor tissue within or...

May 2, 2022

Developments

Zucara Therapeutics secures additional funding to develop ZT-01 for T2D

Closely-held Zucara Therapeutics received second grants from each of GlycoNet and Mitacs to support the development of ZT-01 for the treatment of insulin-induced hypoglycemia in people with Type 2 diabetes. “GlycoNet’s...

May 2, 2022

Developments

First Wave BioPharma fails Phase 2 GI trial to clear SARS-CoV-2

The efficacy endpoint of First Wave BioPharma’s (NASDAQ:FWBI) Phase 2 RESERVOIR trial with FW-COV did not demonstrate statistical significance, compared to placebo, in removing the SARS-CoV-2 virus from the digestive...

May 2, 2022

Developments

Annovis Bio in pact with the National Institute on Aging

Annovis Bio (NYSE:ANVS) entered a cooperative research and development agreement with the NIH’s National Institute on Aging to develop pharmacodynamic biomarkers for buntanetap, focusing on isolating brain-derived...

April 29, 2022

Hepion highlights upcoming Phase 2 rencofilstat trials at NASH Congress

Cowen sees continued demand for Profound’s TULSA-PRO after AUA2022

MindMed reports Phase 1 topline data with MM-110 in opioid withdrawal

Profound Medical insiders add to holdings

Profound Medical’s TULSA-PRO front and center at AUA2022

Ampio board committee conducting internal investigation

Lanier Biotherapeutics to present LNR125 poster at American Thoracic Society

NeoTX acquires InterX to boost drug discovery

Check-Cap initiates U.S. pivotal trial of C-Scan

MindMed collaborators present positive Phase 2 data of LSD in anxiety

Three finalists announced for Bloom Burton Award

Profound Medical nearly doubles Q1 revenue

iBio demonstrates efficacy of an IL-2 sparing anti-CD25 antibody in cancer

Athira Pharma extends open label extension AD studies with fosgonimeton

Rani’s RaniPill wins Fast Company’s 2022 World Changing Ideas Award

Hepion Pharma, HepQuant in clinical collaboration for Phase 2b NASH trial

iBio to present poster highlighting better glycosylation for antibodies produced in plants via its FastPharming System

Profound Medical gets high marks from Cowen on KOL webinar for TULSA-PRO

Limaca Medical receives FDA breakthrough device designation

Zucara Therapeutics secures additional funding to develop ZT-01 for T2D

First Wave BioPharma fails Phase 2 GI trial to clear SARS-CoV-2

Annovis Bio in pact with the National Institute on Aging

General

More